IRVINE, Calif., June 7, 2005 (PRIMEZONE) -- Criticism of President Bush's policy regarding stem cell research by a leading scientist illuminates what could be an advantage for foreign based stem cell research companies, stated SmallCap Sentinel analyst, D.R. Clark.
"In a recently published interview, Woo-Suk Hwang, leader of the South Korean team who cloned the first human embryo for research, said that stem cell science will advance because of its enormous potential and would not be halted by political interests. Clearly, this indicates that one of the field's finest minds believes that non-U.S. based research will continue as domestic efforts are hampered by regulation and law," added Clark.
"This could change the landscape for companies like New Life Scientific (OTCBB:NWLF)," added Clark. "With its access to a Ukraine based stem cell research laboratory well beyond the proverbial arm of U.S. regulation, will it prosper differently if American competition is encumbered by more restrictions on research? Companies focused on stem cell development such as Stemcells Inc. (Nasdaq:STEM), Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq:GERN) must also be pondering geography in their business models."
An informational report regarding New Life Scientific has been made available to the public free of charge at:
http://www.stockupticks.com/news_images/NWLF1.pdf
Individuals may also register free of charge for future reports at the following link:
http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.